The DOI matches its Crossref record.
Ongoing trials with matrix metalloproteinase inhibitors
Abstract
Excessive or poorly regulated matrix metalloproteinase (MMP) activity has been implicated as a pathogenic factor in a range of diseases where the extracellular matrix is degraded or remodelled. Synthetic, potent, low molecular weight MMP inhibitors (MMPIs) have been developed and, over the past five years, these agents have begun clinical testing in patients with cancer, rheumatoid arthritis, osteoarthritis and acute macular degeneration. The past year has seen a number of disappointments with the halting of clinical trials of Ro 32-3555 in patients with rheumatoid arthritis and of BAY 12-9566 in patients with cancer. There have, however, been some successes with perhaps the clearest indication of efficacy being seen in the results of a Phase III trial of marimastat in patients with advanced gastric cancer. Clinical trials are continuing with marimastat and other MMPIs, including prinomastat, solimastat, BMS 275291, metastat and neovastat. Results from these trials are expected in the next two years and it is likely that clinical trials with MMPIs will begin in patients with other diseases where MMPs are believed to be involved, such as restenosis, cerebral haemorrhage and multiple sclerosis. Future research is likely to focus on the identification of specific MMP targets in different diseases, both in order to improve efficacy and to reduce the musculoskeletal side effect profile that has characterised several of the first generation oral MMPIs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations
Coussens, L. M., Fingleton, B., & Matrisian, L. M. (2002) · Science · doi:10.1126/science.1067100 · Cited by 2,761
Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting
Gialeli, C., Theocharis, A. D., & Karamanos, N. K. (2011) · The FEBS Journal · doi:10.1111/j.1742-4658.2010.07919.x · Cited by 1,607
Metalloproteinase inhibitors: biological actions and therapeutic opportunities
Baker, A. H., Edwards, D. R., & Murphy, G. (2002) · Journal of Cell Science · doi:10.1242/jcs.00063 · Cited by 1,179
Davidson, A., & Diamond, B. (2001) · New England Journal of Medicine · doi:10.1056/nejm200108023450506 · Cited by 1,042
Vincenti, M. P., & Brinckerhoff, C. E. (2002) · Arthritis Research & Therapy · doi:10.1186/ar401 · Cited by 796
Pillai, S., Oresajo, C., & Hayward, J. (2005) · International Journal of Cosmetic Science · doi:10.1111/j.1467-2494.2004.00241.x · Cited by 706
Gelatinase-mediated migration and invasion of cancer cells
Björklund, M., & Koivunen, E. (2005) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2005.03.001 · Cited by 661
THE CARDIAC FIBROBLAST: Therapeutic Target in Myocardial Remodeling and Failure
Brown, R. D., Ambler, S. K., Mitchell, M. D., & Long, C. S. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095802 · Cited by 647
Matrix metalloproteinases in cancer: Prognostic markers and therapeutic targets
Vihinen, P., & Kähäri, V. (2002) · International Journal of Cancer · doi:10.1002/ijc.10329 · Cited by 637
Protective strategies against ischemic injury of the liver
SELZNER, N. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)01048-5 · Cited by 546
Chung, T., Moon, S., Chang, Y., Ko, J., Lee, Y., Cho, G., Kim, S., Kim, J., & Kim, C. (2004) · The FASEB Journal · doi:10.1096/fj.04-2126com · Cited by 456
Mor, A., Abramson, S. B., & Pillinger, M. H. (2005) · Clinical Immunology · doi:10.1016/j.clim.2004.12.009 · Cited by 399
Molecular targets of glioma invasion
Nakada, M., Nakada, S., Demuth, T., Tran, N. L., Hoelzinger, D. B., & Berens, M. E. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-6342-5 · Cited by 387
Matrix Metalloproteinase Inhibitor Development and the Remodeling of Drug Discovery
Peterson, J. T. (2004) · Heart Failure Reviews · doi:10.1023/b:hrev.0000011395.11179.af · Cited by 370
Tumor-Associated Macrophages in Breast Cancer
Leek, R. D., & Harris, A. L. (2002) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/a:1020304003704 · Cited by 351
The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia
Klein, G., Vellenga, E., Fraaije, M. W., Kamps, W. A., & de Bont, E. S. J. M. (2004) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2003.09.001 · Cited by 350
Baxter, B. T., Pearce, W. H., Waltke, E. A., Littooy, F. N., Hallett, J. W., Kent, K. C., Upchurch, G. R., Chaikof, E. L., Mills, J. L., Fleckten, B., et al. (2002) · Journal of Vascular Surgery · doi:10.1067/mva.2002.125018 · Cited by 340
Inhibition of ADAM-TS4 and ADAM-TS5 Prevents Aggrecan Degradation in Osteoarthritic Cartilage
Malfait, A.-M., Liu, R.-Q., Ijiri, K., Komiya, S., & Tortorella, M. D. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200431200 · Cited by 294
Ferraris, C., Cavalli, R., Panciani, P. P., & Battaglia, L. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s231479 · Cited by 131
Park, J.-H., Rasch, M. G., Qiu, J., Lund, I. K., & Egeblad, M. (2015) · Neoplasia · doi:10.1016/j.neo.2015.04.003 · Cited by 29
“Despite strong experimental proof that MMPs promote tumor initiation and progression, clinical trials using MMP inhibitors have failed (reviewed in [15,19]).”
Background
Metadata
- Authors
- Brown, P. D.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa Healthcare
- Published
- 2000-09
- Volume
- 9
- Issue
- 9
- Pages
- 2167-2177
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2147160932
- Cited by
- 167
- References
- 0
- FWCI
- 7.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.